Método para promover inmunoterapias

• Main Authors: Hepper, Martin, Leinenbach, Hans Peter, Nocken, Frank
• Format: Patent
• Language: Spanish
• Published: 18.07.2017
• Subjects: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE

Uso de ligandos específicos para anticuerpos autólogos o para antígenos solubles asociados con cáncer, en muestras de sangre para la fabricación de una columna, que exhibe los ligandos unidos a ella, para el tratamiento de cáncer caracterizado porque el tratamiento comprende las etapas de: a) preparación de una muestra de sangre de un paciente; b) someter la muestra de sangre a una inmunoaféresis usando la columna así como administrar al paciente la muestra de sangre tratada de esta manera; c) administración al paciente un anticuerpo con eficacia terapéutica en cuyo caso la sustancia terapéuticamente activa está dirigida contra antígenos asociados al cáncer t. Ex-vivo procedure for increasing the efficacy of active substances binding to antibodies and Fcgamma -receptors, comprises: (a) preparing a blood sample of a patient; (b) subjecting the blood sample to an immunophoresis; and (c) administering an antibody or an Fcgamma -receptor binding active substance to a patient. Independent claims are included for: (1) use of a combination of one or more medicaments with FcR-binding immunoglobulins, fragments of immunoglobulin or fusion proteins, for producing a medicament for treating cancer, autoimmune diseases, transplanted patients and/or for vaccinating against viruses, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering an antibody to a patient; (2) use of specific ligands for body's own antibodies with Fcgamma -receptor binding regions, for producing a column, which exhibits the specific ligand that is coupled to it, for treating a patient with Fcgamma -receptor binding active substances, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering Fcgamma -receptor binding active substances to a patient; (3) use of specific ligands for body's own antibodies for producing a column, which exhibits the ligand that is coupled to it, for treating a patient with antibodies, where the treatment comprises: (a) preparing a blood sample of a patient; (b) subjecting the blood sample to an immunophoresis; (c) administering an antibody to a patient; (4) use of specific ligands for cancer-associated antigens soluble in blood sample for producing a column, which exhibits the ligand that is coupled to it, for treating a patient with therapeutic antibodies, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to an immunophoresis and administering an antibody to a patient; and (5) use of Fcgamma -receptor binding active substances for producing a medicaments for treating cancer, autoimmune diseases, transplanted patients and/or for vaccinating against viruses, where the treatment comprises preparing a blood sample of a patient, subjecting the blood sample to a immunophoresis and administering the medicament to the patients. ACTIVITY : Cytostatic; Immunosuppressive. MECHANISM OF ACTION : None given.